On May 2, 2022, Sorrento announced its Phase I study of intranasal STI-9199 (COVISHIELDTM) had been fully enrolled in healthy volunteers. The study was blinded and ongoing.

The safety profile of STI-9199 (COVISHIELDTM IN) to date was similar to Sorrento’s Phase II compound STI-2099 (COVIDROPSTM) with only transient adverse events, mild in severity and requiring no treatment. This was expected given that in nearly 300 patients treated with COVIDROPSTM, a benign safety profile was also observed.